К слову сказать, работы Чазова Е. по проблемам фибринолиза при атеросклерозе/ИМ также публиковались и в зарубежных журналах в 60-х:
ANTIHEPARIN AND ANTIFIBRINOLYTIC ACTIVITY OF BLOOD IN PATIENTS WITH ATHEROSCLEROSIS.
MYASNIKOV AL, CHAZOV EI.
Am Heart J. 1964 Jan;67:18-22
^^^^^^^^^^
(вышеуказанная публикация была написана на русском самим Чазовым, а спустя 2 года переведена для американского журнала и похоже для полновесности была добавлена фамилия шефа на первое место:
[Antiheparin and antifibrinolytic activity of the blood in atherosclerotic patients].
CHAZOV EI.
Ter Arkh. 1962 Oct;34:36-40. Russian.)
[Plasmin and streptokinase in the treatment of myocardial infarction]
[Article in German].
Chazov EI.
Z Gesamte Inn Med. 1965 Dec 1;20(23):727-30.
но именно публикация в советском Тер.Архиве за 1976 является знаковой:
Treatment of coronary thrombosis with thrombolytic agents was first introduced in the 1950s. Clinical trials, primarily with streptokinase during the 1960s and 1970s, addressed the effects of thrombolysis on mortality rates after acute myocardial infarction, but were inconclusive and largely ignored. In 1976, Chazov et al. from the Soviet Union demonstrated that intracoronary streptokinase !!!согласно оригинальному названию публикации вводился фибринолизин - плохо-очищенная фракция плазмина со следами активаторов плазминогена!!! could produce prompt recanalization of a totally occluded infarct-related artery. In 1980, DeWood et al. demonstrated that 87% of patients with classic Q-wave myocardial infarction had total occlusion from coronary thrombosis of the infarct-related artery when studied during the first 4 hours of their infarction and that 65% of these arteries were still occluded when patients were studied between 12 and 24 hours after infarction. These observations stimulated renewed interest in thrombolytic therapy for acute myocardial infarction...
Heart Lung. 1991 Sep;20(5 Pt 2):538-41.
Overview: rationale of thrombolysis in treating acute myocardial infarction.
Rapaport E.
Department of Medicine, University of California, School of Medicine, San Francisco.
|